The effects of Parvovirus B19 infection on pregnant women and fetus

Yıl 2017, , 62 - 67, 30.12.2017

Fügen Yarkın

https://doi.org/10.5455/jicm.28.20171023

Öz

Background: Human parvovirus B19 infection during
pregnancy may cause fetal loss. The aim of this study was to detect the
incidence of B19 infection in cases of nonimmune hydrops fetalis (NIHF),
spontaneous abortion, intrauterine fetal death (IUFD) and in healthy pregnant
women. Material and Methods: Serum
samples of pregnant women with NIHF (9), spontaneous abortion (27), IUFD (5)
and healthy pregnant women (47) were tested by nested PCR to detect B19 DNA  and by ELISA test for B19 specific IgM and IgG
antibodies. In other case series of the study, paraffin-embedded fetal and
placental tissue samples from 33 NIHF cases and 19 spontaneous abortion cases
and placental tissues from 40 normal pregnant women at term were analyzed for B19 DNA  by nested PCR. Results: B19 infection was diagnosed by PCR and ELISA tests using
serum samples in 4 (44%) of 9 NIHF cases and 9 (33%) of 27 spontaneous abortion
cases and in 1 (20%) of 5 IUFD cases. In addition, B19 IgG prevalence was found
to be 51% (24/47) in the control group. In other case series, the presence of B19 DNA   in
fetal and placental tissue samples was found in 14 (42.4%) of 33 NIHF cases and
6 (31.5%) of 19 spontaneous abortion cases, while in none of 40 placental
tissues samples from the control group. Conclusion:
Our findings show that the incidence of parvovirus B19 infection in NIHF and
spontaneous abortion cases is relatively high. Nested PCR and ELISA tests
should be used together for the early diagnosis of B19 infection in pregnant
women.

Anahtar Kelimeler

Parvovirus B19, Pregnancy, Hydrops fetalis, Polymerase chain reaction (PCR), B19 IgM antibody, B19 IgG antibody

Kaynakça

• 1. Rogo LD, Mokhtari-Azad T, Kabir MH, Rezaei F. Human parvovirus B19: a review. Acta Virol. 2014;58(3):199-213.
• 2. Servant-Delmas A, Lefrère JJ, Morinet F, Pillet S. Advances in human B19 erythrovirus biology. J Virol. 2010;84(19):9658-9665.
• 3. Rogo LD, Mokhtari-Azad T, Kabir MH, Rezaei F.Human parvovirus B19: a review. Acta Virol. 2014;58(3):199-213.
• 4. Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med. 2006;260(4):285-304.
• 5. Giorgio E, De Oronzo MA, Iozza I, Di Natale A, Cianci S, Garofalo G, Giacobbe AM, Politi S. Parvovirus B19 during pregnancy: a review. J Prenat Med. 2010;4(4):63-66.
• 6. Ornoy A, Ergaz Z.Parvovirus B19 infection during pregnancy and risks to the fetus.Birth Defects Res. 2017;109(5):311-323.
• 7. Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Physician. 2007;75(3):373-376.
• 8. Chisaka H, Ito K, Niikura H, Sugawara J, Takano T, Murakami T, Terada Y, Okamura K, Shiroishi H, Sugamura K, Yaegashi N. Clinical manifestations and outcomes of parvovirus B19 infection during pregnancy in Japan. Tohoku J Exp Med. 2006;209(4):277-283.
• 9. Enders M, Weidner A, Enders G.Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany. Epidemiol Infect. 2007;135(4):563-569.
• 10. Zavattoni M, Paolucci S, Sarasini A, Tassis B, Rustico M, Quarenghi A, Piralla A, Baldanti F. Diagnostic and prognostic value of molecular and serological investigation of human parvovirus B19 infection during pregnancy. New Microbiol. 2016;39(3):181-185.
• 11. Broliden K, Tolfvenstam T, Ohlsson S, Henter JI. Persistent B19 parvovirus infection in pediatric malignancies. Med Pediatr Oncol. 1998;31(2):66-72.
• 12. 12- de Jong EP, Walther FJ, Kroes AC, Oepkes D. Parvovirus B19 infection in pregnancy: new insights and management. Prenat Diagn. 2011;31(5):419-425.
• 13. Lamont RF, Sobel JD, Vaisbuch E, Kusanovic JP, Mazaki-Tovi S, Kim SK, Uldbjerg N, Romero R. Parvovirus B19 infection in human pregnancy. BJOG. 2011;118(2):175-186.
• 14. Staroselsky A, Klieger-Grossmann C, Garcia-Bournissen F, Koren G. Exposure to fifth disease in pregnancy. Can Fam Physician. 2009;55(12):1195-1198.
• 15. Tolfvenstam T, Broliden K. Parvovirus B19 infection. Semin Fetal Neonatal Med. 2009;14(4):218-221.
• 16. Chisaka H, Morita E, Yaegashi N, Sugamura K. Parvovirus B19 and the pathogenesis of anaemia. Rev Med Virol. 2003;13(6):347-359.
• 17. Landry ML. Parvovirus B19. Microbiol Spectr. 2016 Jun; 4(3). doi:10.1128/microbiolspec.
• 18. Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn. 2004;24(7):513-518.
• 19. Yaegashi N, Niinuma T, Chisaka H, Watanabe T, Uehara S, Okamura K, Moffatt S, Sugamura K, Yajima A. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. J Infect. 1998;37(1):28-35.
• 20. Da Silva AR, Nogueira SA, Alzeguir JC, da Costa MC, do Nascimento JP. Anti-parvovirus B19 IgG antibody prevalence in pregnant women during antenatal follow-up and cases of non-immune hydropsis fetalis due to parvovirus B19, in the City of Rio de Janeiro. Rev Soc Bras Med Trop. 2006;39(5):467-472.
• 21. Ergunay K, Altinok G, Gurel B, Pinar A, Sungur A, Balci S, Ustacelebi S. Identifying the etiologic role of Parvovirus B19 in non-immune hydrops fetalis by histopathology, immunohistochemistry and nucleic acid testing: a retrospective study. Central European Journal of Medicine. 2007;2(3):271-279.
• 22. Carlsen KM.Human parvovirus B19 erythrovirus. Methods established for virological and diagnostic aspects. APMIS Suppl. 2006;(120):1-121.
• 23. Quemelo PR, Lima DM, da Fonseca BA, Peres LC. Detection of parvovirus B19 infection in formalin-fixed and paraffin-embedded placenta and fetal tissues. Rev Inst Med Trop Sao Paulo. 2007;49(2):103-107.
• 24. Landolsi H, Yacoubi MT, Bouslama L, Lahmar A, Trabelsi A, Hmissa S, et al. Detection of the human Parvovirus B19 in nonimmune hydrops fetalis using immunohistochemistry and nested-PCR in formalin-fixed and paraffin-embedded placenta and fetal tissues. Pathol Biol (Paris). 2009 May;57(3):e1-7.
• 25. Jordan JA. Identification of human Parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol 1996;174(1 Pt 1):37–42.
• 26. Mark Y, Rogers BB, Oyer CE. Diagnosis and incidence of fetal parvovirus infection in an autopsy series: II. DNA Amplification. J. Pediatr. Pathol. 1993; 13: 381–386.
• 27. Salakawy A., Mohammed N, Shaker O. Human Parvovirus B19, Cytomegalovirus Infections and Thyroid Autoimmunity in Women with Recurrent First Trimester Abortion. The Egyption Journel Of Hospital Medicine 2000;1:33-47.
• 28. El-Sayed Zaki M, Goda H. Relevance of parvovirus B19, herpes simplex virus 2, and cytomegalovirus virologic markers in maternal serum for diagnosis of unexplained recurrent abortions. Arch Pathol Lab Med. 2007;131(6):956-960.
• 29. Kishore J, Gupta I. Serological study of parvovirus B19 infection in women with recurrent spontaneous abortions. Indian J Pathol Microbiol. 2006;49(4):548-550.
• 30. Tolfvenstam T, Papadogiannakis N, Norbeck O, Petersson K, Broliden K. Frequency of human parvovirus B19 infection in intrauterine fetal death. Lancet. 2001;357(9267):1494-1497.
• 31. Wang R, Chen X, Han M. Relationship between human parvovirus B19 infection and spontaneous abortion. Zhonghua Fu Chan Ke Za Zhi. 1997;32(9):541-543.
• 32. Xu D, Zhang G, Wang R. The study on detection of human Parvovirus B19 DNA in spontaneous abortion tissues. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi.1998;12(2):158-160.
• 33. Xu D, Zhang G, Li B, Wang X, Sun X. Relationship between human parvovirus B19 infection and spontaneous abortion and congenital heart disease in China. Zhonghua Fu Chan Ke Za Zhi. 2002;37(6):324-326.
• 34. Skjöldebrand-Sparre L, Tolfvenstam T, Papadogiannakis N, Wahren B, Broliden K, Nyman M. Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG. 2000;107(4):476-480.
• 35. Petersson K, Norbeck O, Westgren M, Broliden K. Detection of parvovirus B19, cytomegalovirus and enterovirus infections in cases of intrauterine fetal death. J Perinat Med. 2004;32(6):516-521.
• 36. Pedranti MS, Adamo MP, Macedo R, Zapata MT. Prevalence of anti-rubella and anti-parvovirus B19 antibodies in pregnant women in the city of Córdoba, and in women of fertile age in the city of Villa Mercedes, province of San Luis. Rev Argent Microbiol. 2007;39(1):47-50.
• 37. Alanen A, Kahala K, Vahlberg T, Koskela P, Vainionpää R. Seroprevalence, incidence of prenatal infections and reliability of maternal history of varicella zoster virus, cytomegalovirus, herpes simplex virus and parvovirus B19 infection in South-Western Finland. BJOG. 2005;112(1):50-56.
• 38. Enders M, Weidner A, Enders G. Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany. Epidemiol Infect. 2007;135(4):563-569.
• 39. Van Gessel PH, Gaytant MA, Vossen AC, Galama JM, Ursem NT, Steegers EA, et al. Incidence of parvovirus B19 infection among an unselected population of pregnant women in the Netherlands: A prospective study. Eur J Obstet Gynecol Reprod Biol. 2006;128(1-2):46-49.
• 40. Jensen IP, Thorsen P, Jeune B, Møller BR, Vestergaard BF. An epidemic of parvovirus B19 in a population of 3,596 pregnant women: a study of sociodemographic and medical risk factors. BJOG. 2000;107(5):637-643.
• 41. Vyse AJ, Andrews NJ, Hesketh LM, Pebody R. The burden of parvovirus B19 infection in women of childbearing age in England and Wales. Epidemiol Infect. 2007;135(8):1354-1362.
• 42. Mossong J, Hens N, Friederichs V, Davidkin I, Broman M, Litwinska B, et el. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. Epidemiol Infect. 2008;136(8):1059-1068.